Latest News

(UroToday.com) One mainstay of treatment in advanced renal cell carcinoma are tyrosine kinase inhibitors against multiple signaling pathways active in this disease. Paradoxically, molecular profiling is not routinely used prior to initiation of treatment in RCC. In the past few years, multiple efforts have been undertaken to determine predictive molecular biomarkers associated with response to treatment […]

(UroToday.com) Sunitinib has been the standard first-line treatment for metastatic clear cell RCC since 2007. However, nivolumab plus ipilimumab combination therapy has been recently approved in upfront treatment of metastatic clear cell RCC patients with IMDC intermediate/poor risk groups based on data in the CheckMate-214 trial.1 In this trial, the objective response rate (ORR) was 42% […]

(UroToday.com) Cabozantinib inhibits tyrosine kinases including MET, VEGF receptors, and TAM family of kinases (TYRO3, MER, and AXL). Furthermore, cabozantinib is a standard-of-care for the treatment of advanced RCC, in addition to promoting an immune-permissive environment that may enhance response to immune checkpoint inhibitors. In combination with immune checkpoint inhibitors, cabozantinib has shown promising activity for […]

Prof. Hein van Poppel at the European Parliament on World Cancer Day (4 February 2020) In its constant devotion to improving patient care, the EAU has become increasingly active in the European political landscape. Prof. Hein Van Poppel (Leuven, BE), Adjunct Secretary General responsible for education, is the driving force behind the EAU’s activities in […]

YouTube is a social media platform with more than 1 billion users and >600000 videos about prostate cancer. Two small studies examined the quality of prostate cancer videos on YouTube, but did not use validated instruments, examine user interactions, or characterize the spread of misinformation.

Cytotoxic chemotherapy can cure advanced germ cell tumors. Nevertheless, cancer treatment may induce cellular senescence and accelerate molecular aging. The aging process implies an increase of cells expressing p16INK4a and changes in lymphocyte subpopulations.

To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic resonance imaging-targeted needle biopsy.

Prostate cancer (PCa) is the second most common male cancer in the world. Its incidence is estimated to grow to 1.7 million new cases and 499,000 new deaths by 2030. Treatment of OCPC can affect patients physically and mentally, as well as their close relationships and their job or career, which conditions health-related quality of […]

Androgen deprivation therapy (ADT) is a cornerstone treatment for locally advanced or metastatic prostate cancer (PCa). However, its potential effects on the tumor immune microenvironment (TIM) of PCa patients and the underlying mechanism remain largely unclear.

We compared upgrading and upstaging rates in low risk and favorable intermediate risk prostate cancer (CaP) patients according to racial and/or ethnic group: Mexican-Americans and Caucasians. Within Surveillance, Epidemiology and End Results database (2010-2015), we identified low risk and favorable intermediate risk CaP patients according to National Comprehensive Cancer Network guidelines.